Esophageal Neoplasm Clinical Trial
Official title:
Intraoperative Volume Restriction in Esophageal Carcinoma Surgery: an Exploratory Randomized Clinical Trial
An exploratory single-centre randomized clinical trial was performed in order to investigate whether the fluid volume administered during esophageal carcinoma surgery affects pulmonary gas exchange and tissue perfusion.
A convenience sample of 16 patients admitted to the Department of Thoracic surgery
University Hospital Centre Zagreb and scheduled for esophageal carcinoma surgery were
enrolled prospectively in the study between June 2011 and August 2012.
Patients were randomly allocated into two groups, one of which received ≤ 8ml/kg/h of
intraoperative fluid ("restrictive group") and another that received > 8 ml/kg/h of fluid
("liberal group").
Patients were excluded if they were younger than 18 years; if they had severe lung disease,
chronic renal insufficiency, or a physical status classification > III on the American
Society of Anesthesiologists (ASA) scale; or if it was impossible to perform epidural
catheter placement or thoraco-phreno-laparotomy.
All patients underwent esophagectomy carried out according to the Lewis-Tanner approach.
Data on arterial oxygen partial pressure (PaO2), inspired oxygen fraction (FiO2), and the
ratio PaO2/FiO2 were collected 10 min after anesthesia was induced and again 6 h after
surgery. Data on the metabolic markers creatinine and lactate were collected 10 min after
anesthesia induction and 6 h after surgery.
ANOVA tests were performed to determine significant differences in mean values between study
groups. Independent-sample t-tests were used to test differences in mean values between the
restrictive and liberal groups for each of the two sets of measurements separately (10
minutes after anesthesia induction and 6 hr after surgery). P < 0.05 was considered
significant.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05406024 -
Feasibility Study CORPPS
|
||
Terminated |
NCT02601079 -
Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis
|
N/A | |
Active, not recruiting |
NCT01745107 -
Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
|
Phase 3 | |
Active, not recruiting |
NCT02969473 -
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04481100 -
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Terminated |
NCT01870791 -
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00431756 -
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
|
||
Not yet recruiting |
NCT05736705 -
Monopolar and Bipolar in Esophageal ESD
|
N/A | |
Completed |
NCT02395705 -
Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
|
Phase 3 | |
Terminated |
NCT00653107 -
Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only
|
Phase 3 | |
Completed |
NCT01927016 -
Outcomes After Esophageal Cancer Surgery
|
N/A | |
Completed |
NCT02558504 -
Radiofrequency in the Treatment of Barrett's Oesophagus
|
Phase 4 | |
Active, not recruiting |
NCT02636088 -
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT00423150 -
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
|
Phase 2 | |
Completed |
NCT00318903 -
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT02583087 -
ESD for the Treatment of Early Barrett's Neoplasia
|
N/A | |
Active, not recruiting |
NCT04489368 -
Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning
|